Study finds expanded predictive value of Breast Cancer Index for ovarian function suppression in SOFT trial

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.

Imlunestrant improves PFS in breast cancer, phase III data show

Eli Lilly and Co. announced results from the phase III EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, in patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.

AI test is equivalent to Oncotype DX at predicting breast cancer recurrence, study shows

COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.

Genetic disposition increases the risk of breast cancer metastasis

For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA.

Kisqali shows reduction in distant recurrence in early breast cancer, phase III data show

Novartis announced results from an updated analysis of the pivotal phase III NATALEE trial of Kisqali (ribociclib) that underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy. Results showed a sustained reduction in distant recurrence of 28.5% (HR=0.715; 95% CI 0.604-0.847; nominal P<0.0001), compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.